The US pharmacy giant CVS Health is to contract with global biosimilars player Sandoz to commercialize and bring to market its Hyrimoz (adalimumab-adaz) biosimilar to Humira as the first product imagined by the launch of its wholly owned US biosimilars subsidiary called Cordavis.
CVS Lines Up Sandoz’s Adalimumab Biosimilar For US Biosimilars Subsidiary
Hyrimoz 100mg/ml To Launch Q1 2024; Business Will ‘Expand Supply Chain’
CVS feels its newly launched, wholly owned US biosimilars subsidiary called Cordavis is a “logical evolution for us and will help ensure sufficient supply of biosimilars in the US and support this market now and in the future.”
More from Biosimilars
• By
Organon has swelled its immunology biosimilar portfolio after acquiring the US commercial rights to Bio-Thera’s tocilizumab biosimilar from Biogen, which last year decided to retain its interests in biosimilars following a lengthy strategic review.
• By
Alvotech has named two new key executives, while Biosimilars Canada has elected its 2025 leaders and the AAM has welcomed the new FDA commissioner in the US.
Gedeon Richter has filed its Mochida-partnered tocilizumab biosimilar rival to RoActemra with the European Medicines Agency. But with several biosimilars already having won approval, the market could be competitive.
• By
Accord received positive opinions for its Prolia and Xgeva biosimilars at the latest meeting of the EMA’s CHMP. Meanwhile, Celltrion picked up a nod for another Stelara biosimilar, while Rechon Life Science withdrew an application for human insulin.
More from Products
• By
Teva should not be able to overturn European fines imposed over a historical “pay-for-delay” arrangement covering Cephalon’s Provigil (modafinil), an advocate general of the CJEU has recommended.
• By
Alvotech has named two new key executives, while Biosimilars Canada has elected its 2025 leaders and the AAM has welcomed the new FDA commissioner in the US.
Gedeon Richter has filed its Mochida-partnered tocilizumab biosimilar rival to RoActemra with the European Medicines Agency. But with several biosimilars already having won approval, the market could be competitive.